Mycamine Micafungin Sodium for Injection

1. Indications and Usage
Invasive Candidiasis: Treatment of candidemia and other forms of invasive candidiasis, including intra-abdominal abscesses and peritonitis.
Esophageal Candidiasis: Treatment of esophageal candidiasis.
Prophylaxis in Hematopoietic Stem Cell Transplant Recipients: Prophylaxis of fungal infections in patients undergoing hematopoietic stem cell transplantation.
Recurrent Invasive Aspergillosis: Treatment of recurrent or refractory invasive aspergillosis in patients who are intolerant to other therapies.
2. Dosage and Administration
Adults: The usual dosage for candidemia/invasive candidiasis is 100 mg once daily. For esophageal candidiasis, 150 mg once daily is recommended.
Pediatrics: For neonates and infants, the dosage is typically 2-3 mg/kg once daily.
Administration: Administer via intravenous infusion diluted in 0.9% sodium chloride or 5% dextrose. The infusion rate should be controlled (typically over 1 hour).
Renal/Hepatic Impairment: No dosage adjustment is required for mild to moderate hepatic impairment or any degree of renal impairment.
3. Mechanism of Action
Cell Wall Synthesis Inhibition: Micafungin inhibits β-(1,3)-D-glucan synthase, an enzyme complex in fungal cell membranes. This blocks the synthesis of β-(1,3)-D-glucan, an essential component of the fungal cell wall, leading to cell lysis and death.
4. Safety and Warnings
Hepatotoxicity: Elevations in liver enzymes (AST, ALT, ALP) and cases of hepatotoxicity have been reported.
Infusion-Related Reactions: Histamine-mediated reactions, such as flushing, rash, pruritus, and hypotension, may occur during infusion.
Hematologic Abnormalities: Neutropenia, thrombocytopenia, and hemolysis (including intravascular hemolysis) have been observed.
Fetal/Neonatal Toxicity: Based on animal studies, micafungin may cause fetal harm.
5. Adverse Reactions and Clinical Research
Common: Gastrointestinal disturbances (diarrhea, nausea), elevated liver enzymes, headache, and peripheral edema.
Serious: Anaphylaxis, severe skin reactions (Stevens-Johnson syndrome), and acute renal failure.
Clinical Research: Clinical trials have demonstrated superior efficacy and a favorable safety profile compared to amphotericin B deoxycholate in the treatment of esophageal candidiasis.
6. Drug Interactions
Cyclosporine: Concomitant use may increase the exposure of micafungin.
Nifedipine, Tacrolimus, Sirolimus: Micafungin may increase the plasma concentrations of these drugs due to inhibition of CYP3A4 or P-gp, potentially increasing their toxicity.
Voriconazole: Concomitant use decreases micafungin exposure and may reduce its efficacy.
7. Pharmaceutical Information
Active Ingredient: Micafungin Sodium.
Excipients: Mannitol, citric acid, sodium hydroxide.
Appearance: White lyophilized powder or block-like substance.
Storage: Store in a well-sealed container at 25°C; protect from light.